

EMA/532157/2021

European Medicines Agency decision P/0455/2021

of 29 October 2021

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for glepaglutide, (EMEA-002926-PIP01-20) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0455/2021

of 29 October 2021

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for glepaglutide, (EMA-002926-PIP01-20) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Zealand Pharma A/S on 26 November 2020 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 10 September 2021, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for glepaglutide, solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for glepaglutide, solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for glepaglutide, solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Zealand Pharma A/S, Sydmarken 11, 2860 – Søborg, Denmark.

EMA/PDCO/333001/2021
Amsterdam, 10 September 2021

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-002926-PIP01-20

Scope of the application

Active substance(s):

Glepaglutide

Condition(s):

Treatment of short bowel syndrome

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

Zealand Pharma A/S

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Zealand Pharma A/S submitted for agreement to the European Medicines Agency on 26 November 2020 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 4 January 2021.

Supplementary information was provided by the applicant on 4 June 2021. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
 - to grant a deferral in accordance with Article 21 of said Regulation;
 - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of short bowel syndrome

The waiver applies to:

- the paediatric population from birth to less than 4 months of age;
- solution for injection, subcutaneous use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition:

Treatment of short bowel syndrome

2.1.1. Indication(s) targeted by the PIP

Treatment of patients with short bowel syndrome (SBS)

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 4 months to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Solution for injection

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable
Non-clinical studies	2	Study 1 Dose range-finding juvenile toxicity study in rats (Covance study no.: YT76NV, Zealand Pharma study no.:19-069) Study 2 Definitive juvenile toxicity study in rats
Clinical studies	2	Study 3 Multi-centre, randomized, single-blinded, 24-week, two-dose efficacy, safety and pharmacokinetic (PK) study in children aged 4 months to less than 18 years with short

		bowel syndrome (SBS) and requiring parenteral support (PS) Study 4 Multi-centre, single-blinded, two-dose 104 weeks extension trial to evaluate long-term safety (including an evaluation of the immunogenic potential of glepaglutide) and efficacy in children aged 4 months to less than 18 years with short bowel syndrome (SBS) and requiring parenteral support (PS)
Extrapolation, modelling and simulation studies	1	Study 5 Population PK dose finding study
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By December 2029
Deferral for one or more measures contained in the paediatric investigation plan:	Yes